RecruitingPhase 1NCT06034275

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies

Sponsor

Vincerx Pharma, Inc.

Enrollment

36 participants

Start Date

Sep 13, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia B-cell Acute Lymphoblastic Leukemia

Summary

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called VIP943 for people with advanced blood cancers — specifically acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) — who have run out of standard treatment options. **You may be eligible if...** - You are 18 or older - You have confirmed AML, B-ALL, or MDS - You have exhausted all available standard therapies, or are not eligible for them - Your cancer cells express a protein called CD123 (confirmed by a lab test) - You are in reasonable functional health (ECOG 0–2) **You may NOT be eligible if...** - The cancer has spread to the brain or spinal fluid - You have significant heart failure or recent heart attack or unstable chest pain - You have other significant uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.